WO2019175761A1 - Ready to use dantrolene compositions - Google Patents

Ready to use dantrolene compositions Download PDF

Info

Publication number
WO2019175761A1
WO2019175761A1 PCT/IB2019/051986 IB2019051986W WO2019175761A1 WO 2019175761 A1 WO2019175761 A1 WO 2019175761A1 IB 2019051986 W IB2019051986 W IB 2019051986W WO 2019175761 A1 WO2019175761 A1 WO 2019175761A1
Authority
WO
WIPO (PCT)
Prior art keywords
dantrolene
composition
solvent system
aqueous solvent
aqueous
Prior art date
Application number
PCT/IB2019/051986
Other languages
French (fr)
Inventor
Mailatur Sivaraman Mohan
Hiren Patel
Bhaveshkumar VALLABHBHAI PATEL
Raghu KANNEKANTI
Babuji KANTU
Ragneshkumar PATEL
Original Assignee
Orbicular Pharmaceutical Technologies Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orbicular Pharmaceutical Technologies Private Limited filed Critical Orbicular Pharmaceutical Technologies Private Limited
Publication of WO2019175761A1 publication Critical patent/WO2019175761A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Definitions

  • the present invention relates to a stable, multidose, ready to use, non- aqueous compositions comprising (i) dantrolene or pharmaceutically acceptable salts thereof; (ii) non-aqueous solvent system suitable for injection, wherein dantrolene was substantially dissolved in the non-aqueous solvent system; wherein non-aqueous solvent system is free of polar aprotic solvents.
  • Dantrolene 1 -[(E)-[5-(4-nitrophenyl) furan-2-yl] methylideneamino] imidazolidine-2,4-dione, is a direct-acting skeletal muscle relaxant. It is the rescue agent of choice in the treatment of malignant hyperthermia, therefore widely available in most locations where anesthetics are delivered.
  • the commercial formulation Ryanodex ® for injectable suspension is a sterile lyophilized powder comprising mannitol, polysorbate 80, povidone K12 and sodium hydroxide or hydrochloric acid for pH adjustment.
  • Reconstituted RYANODEX ® was administered by intravenous push at a minimum dose of 1 mg/kg for the treatment of malignant hyperthermia, whereas the
  • RYANODEX is 2.5 mg/kg administered intravenously over a period of at least 1 minute, starting approximately 75 minutes prior to surgery.
  • Dantrium ® is a sterile, non-pyrogenic, lyophilized formulation of dantrolene sodium for injection comprising 3000 mg mannitol, and sufficient sodium hydroxide. Dantrium ® intravenous should be administered by continuous rapid intravenous push beginning at a minimum dose of 1 mg/kg, and continuing until symptoms subside or the maximum cumulative dose of 10 mg/kg has been reached.
  • U.S. Pat. No. 5,091 ,188 discloses, water-insoluble drugs injectable formulations as aqueous suspensions of phospholipid-coated microcrystals.
  • Example 14 illustrates the lecithin-coated microcrystals of dantrolene.
  • U.S. Pat. No. 7,758,890 discloses low volume, safe for injection, colloidal dispersion of dantrolene sodium, water soluble polysorbate, dispersing agents like sorbitol and mannitol and water as a liquid carrier.
  • Examples 1 -3 illustrates dantrolene colloidal suspension formulations and their preparation process.
  • U.S. Patent Application No 2003/0045587 discloses a pharmaceutical composition
  • a pharmaceutical composition comprising dantrolene sodium and a solvent system comprising polar organic material comprising a sugar having at least two hydroxyl groups or an alcohol of two or three carbons having at least two hydroxyl groups or both and a second polar organic material comprising an amide group or an ammonium group or both.
  • polar solvent system comprising glycerol and N, N-dimethylacetamide (DMA).
  • The‘587 application aimed at developing formulations of dantrolene in a mixture of N, N-dimethylacetamide and glycerol (illustrated in examples 1 -5 preferably contain) are not recommended/suitable for injection because of DMA toxicity profile.
  • U.S. Pat. No. 9,433,608 discloses an emulsion prepared by mixing a component comprising val-dantrolene in glycerine or Vitamin E with another component comprising dantrolene in polyethylene glycol/propylene glycol/pluronic acid.
  • U.S. Patent Application No. 2004/0242646 discloses low volume safe for injection aqueous composition
  • dantrolene sodium and liquid carriers selected from group consisting of water, a water miscible solvent, glycerol, propylene glycol, dimethylacetamide, ethanol, polyethylene glycol, triethyl citrate, triacetin, monothioglycerol, or mixtures thereof.
  • examples 1 -3 illustrates dantrolene colloidal suspension formulations and their preparation process. There has been no disclosure on the use of liquid carrier in preparing liquid compositions and their stability.
  • non-aqueous solvents or solvent systems for the preparation of dantrolene compositions has been disclosed in the scientific and patent literatures (see for example U.S. 2003/0045587), there has been no disclosure of non-aqueous ready to use dantrolene compositions comprising high concentration of dantrolene.
  • compositions comprising dantrolene and non-aqueous solvent systems.
  • the compositions of the present invention wherein dantrolene was substantially dissolved in the non-aqueous solvent system and the non- aqueous solvent system is free of polar aprotic solvents.
  • the compositions of the present invention are stable for commercially significant time and also suitable for direct or instant administration.
  • the present invention relates to a stable, multidose, ready to use, non- aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection which is free from polar aprotic solvents.
  • the object of the invention is to prepare a stable, multidose, ready to use, non-aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection; wherein dantrolene was substantially dissolved in the non-aqueous solvent system.
  • dantrolene compositions in non-aqueous solvent systems which are free from polar aprotic solvents provides a stable, multidose, ready to use compositions.
  • a stable, multidose, ready to use, non-aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein
  • compositions comprising from about 50 mg/mL to about 150 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
  • the present invention relates to a stable, multidose, ready to use, non- aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system selected from the group comprising glycerol, propylene glycol, ethanol, polyethylene glycol, methanol, 1 -Butanol, 2-butanol, tertiary butanol, isopropanol, 1 -propanol and mixtures thereof.
  • non- aqueous solvent system selected from the group comprising glycerol, propylene glycol, ethanol, polyethylene glycol, methanol, 1 -Butanol, 2-butanol, tertiary butanol, isopropanol, 1 -propanol and mixtures thereof.
  • non-aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system preferably comprising propylene glycol, polyethylene glycol, ethanol and combinations thereof.
  • stability of high concentrations (at least about 5%, w/v) of compound has been provided by the formulations of the present invention.
  • the present invention relates to a stable, multidose, ready to use, non- aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein the compositions further comprises at least one pharmaceutically acceptable excipients selected form the group of solubilizers, stabilizers, buffering agents, tonicity contributing agents, pH adjusting agents.
  • the present invention relates to a stable, multidose, ready to use, non- aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein the compositions is having a pH ranging from about 5.0 to about 1 1.
  • PDIT psychostimulant drug-induced toxicity
  • the present invention relates to a stable, multidose, ready to use, non- aqueous compositions comprising (i) dantrolene or pharmaceutically acceptable salts thereof, (ii) non-aqueous solvent system suitable for injection; wherein dantrolene was substantially dissolved in the non-aqueous solvent system; wherein non-aqueous solvent system is free of polar aprotic solvents.
  • the present invention drawn to unexpected discovery of stable, ready to use, compositions of dantrolene in non-aqueous solvent system free from polar aprotic solvents.
  • dantrolene includes the compound dantrolene
  • ready-to-use refers to a liquid for parenteral administration that is not obtained by reconstituting a lyophilized product.
  • composition and“formulation” refer to preparations comprising dantrolene or pharmaceutically acceptable salts thereof; in a form suitable for administration to a mammal.
  • substantially dissolved relates to 0.1 % to 99% of total dantrolene is dissolved in the compositions.
  • Stability includes both physical and chemical stability. Stability parameters include but not limited to potency, stable pH value and other physico-chemical parameters.
  • compositions free from particles and that do not significantly change during storage refers to compositions free from particles and that do not significantly change during storage.
  • polar aprotic solvents relates to a polar solvent that lack an acidic hydrogen and do not participate in hydrogen bonding (lack of O-H or N- H bonds), for example N, N-dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), dimethylformamide (DMF), hexamethyl phosphorotriamide (HMPT), dichloromethane, hydro furans (e.g. tetrahydrofuran), hydro pyrans, ethyl acetate, acetone, acetonitrile, propylene carbonate, N-methyl-2-pyrrolidone, and the like.
  • DMA N-dimethylacetamide
  • DMSO dimethyl sulfoxide
  • DMF dimethylformamide
  • HMPT hexamethyl phosphorotriamide
  • dichloromethane hydro furans (e.g. tetrahydrofuran), hydro pyrans, ethyl acetate, acetone, ace
  • non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection.
  • non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein dantrolene was substantially dissolved in the non-aqueous solvent system.
  • non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein dantrolene was substantially dissolved in the non-aqueous solvent system; wherein non- aqueous solvent system is free of polar aprotic solvents.
  • the stable, multidose, ready to use, non-aqueous composition comprising from about 10 mg/mL to about 200 mg/mL or from about 25 mg/ml to about 175 mg/ml or from about 50 mg/ml to about 150 mg/ml of dantrolene or pharmaceutically acceptable salts thereof.
  • composition comprising combination of dantrolene with other agents within the scope of the invention for example azumolene, NMDA blocker, benzodiazepine derivatives and the like, combinations thereof.
  • the non-aqueous solvent system comprises non- aqueous solvents and their mixture thereof.
  • non-aqueous solvent system is free from polar aprotic solvents.
  • the composition comprising less than 5% by weight of residual water content.
  • This residual water content may have contributed from the non-aqueous solvents used in the composition.
  • the composition comprising less than 2.5% by weight of residual water content.
  • suitable non-aqueous solvents comprise, polar protic solvents and mixtures thereof.
  • the polar protic solvents are known in the art and include alkyl alcohols, for example ethanol, methanol, 1 -butanol, 2-butanol, 1 -propanol, isopropanol, tertiary butanol; alkyl glycols for example, ethylene glycol, propylene glycol and butylene glycol; glycerin; polyalkylene glycols, such as polyethylene glycol, polypropylene glycol, and polybutylene glycol.
  • non-aqueous solvents selected from the group comprising glycerol, propylene glycol, ethanol, polyethylene glycol, methanol, acetone, acetonitrile, 1 -Butanol, 2-butanol, tertiary butanol, isopropanol, 1 - propanol, and mixtures thereof.
  • non-aqueous solvent system preferably comprising propylene glycol, polyethylene glycol, ethanol and/or combinations thereof.
  • non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof; non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system comprises of polyethylene glycol.
  • non- aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof; non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system comprises the mixture of polyethylene glycol and propylene glycol.
  • non- aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof; non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system comprises the mixture of polyethylene glycol and ethanol.
  • the stable, multidose, ready to use, non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof; non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system comprises of propylene glycol.
  • the stable, multidose, ready to use, non- aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof; non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system comprises the mixture of propylene glycol and ethanol.
  • non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof; non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system comprises the mixture of polyethylene glycol, propylene glycol and ethanol.
  • the PEG has a molecular weight ranging from about 100 g/mol to about 2,500 g/mol.
  • the PEG has a molecular weight ranging from between about 300 g/mol to about 1000 g/mol.
  • the PEG has an average molecular weight ranging from between about 400 g/mol to about 800 g/mol.
  • exemplary PEG’S include PEG-300, PEG-400, PEG-600 and PEG-800.
  • polypropylene glycol may have a molecular weight ranging from about 200 g/mol to about 2500 g/mol.
  • exemplary poly propylene glycols include PPG-250, PPG-425, and PPG-700.
  • composition comprising propylene glycol in a range from about 30% to about 90% by weight of the composition
  • composition comprising propylene glycol in a range from about 10% to about 90% by weight of the composition.
  • composition comprising polyethylene glycol in a range from about 30% to about 90% by weight of the composition.
  • composition comprising ethanol in a range from about 5% to about 50% by weight of the composition.
  • the stable, multidose, ready to use, non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection and at least one pharmaceutically acceptable excipient selected form the group of solubilizers, stabilizers, buffering agents, tonicity contributing agents, pH adjusting agents.
  • the stable, multidose, ready to use, non-aqueous composition comprising tonicity contributors including one or more of sodium chloride, potassium chloride, and alkaline substances including one or more of sodium hydroxide, potassium hydroxide, sodium carbonate and meglumine and salts.
  • solvent refers to any substance which enhances the solubility of the dantrolene in the solvents.
  • Suitable solubilizer comprises, but not limited to, carboxylic acid, sugar and tromethamine.
  • Suitable carboxylic acid comprises, but not limited to, citric acid, malic acid, tartaric acid, succinic acid, acetic acid and the like.
  • Suitable sugar comprises, but not limited to, monosaccharide, disaccharide and reduced sugars that are suitable for administration by subcutaneous and intravenous routes.
  • Some examples of sugar include, but not limited to, sucrose, fructose, trehalose, xylitol, mannitol, sorbitol and the like.
  • non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein the composition is having a pH ranging from about 5.0 to about 11.
  • non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein the composition is having a pH ranging from about 7.0 to about 11.
  • stabilizer refers to an agent which improves the composition stability.
  • suitable stabilizers includes surfactants,
  • antioxidants include antioxidants, chelating agents, proteins, polymers and combinations thereof.
  • stabilizers include antioxidants selected from the group, but not limited to butylated hydroxyanisole (BHA), butylated hydroxyl toluene (BHT), ascorbic acid and their esters, lactic acid, benzoic acid, tocopherol (Vitamin E) and its derivatives, sodium metabisulfite, sodium bisulfite, sodium sulfite, sodium bisulfate, sodium thiosulfate, sodium acetate trihydrate, sodium formaldehyde sulfoxylate, monothioglycerol, L-cysteine, parabens, benzyl alcohol, thiourea, propyl gallate, methionine, thioglycolic acid, tartaric acid, phosphoric acid, gluconic acid, thiodipropionic acid, acetonic dicarboxylic acid, amino acids such as histidine, tryptophan, tyrosine;
  • antioxidants selected from the group, butylated
  • Chelating agents include, but are not limited to, edetate salts, for example, edetate disodium and citric acid, ethylene glycol-bis(beta-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA) and 8-Amino-2-[(2-amino-5- methylphenoxy)methyl]-6-methoxyquinoline-N,N,N’N’-tetraacetic acid, tetrapotassium salt (QUIN-2) and the like combinations thereof.
  • edetate salts for example, edetate disodium and citric acid, ethylene glycol-bis(beta-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA) and 8-Amino-2-[(2-amino-5- methylphenoxy)methyl]-6-methoxyquinoline-N,N,N’N’-tetraacetic acid,
  • proteins as stabilizers include albumin, casein, and salts of casein;
  • Polymers include polyvinylpyrrolidone (PVP), acacia (gum arabic), carmellose sodium, dextran, collagen, gelatin, gelatin hydrosylate, sodium starch glycolate, inulin, and xanthan;
  • suitable surfactants or block copolymer components include cationic surfactants, anionic surfactants, non-ionic surfactants, zwitterionic surfactants, PEGylated surfactants, block copolymer and mixtures thereof.
  • polysorbates sodium oleate, sodium dodecyl sulfate, sodium diethyl hexyl sulfosuccinate, sodium dimethyl hexyl sulfosuccinate, sodium di-2-ethyl acetate, sodium 2-ethylhexyl sulfate, sodium undecane-3-sulfate, sodium ethyl phenyl undecanoate, dimethylammonium and trimethylammonium
  • ammoniopropane- 1 -sulfate dodecyl dimethyl ammoniobutyrate
  • castor oil derivatives such as Cremaphore EL, Arlatone G, sorbitan
  • the dantrolene compositions of the present invention can be packaged in any suitable sterile vial or container fit for the sterile storage of a pharmaceutical such as dantrolene for extended periods of time.
  • Suitable containers can be glass vials, i.e. treated vials, molded glass vials, and CZ resin vials, polypropylene or polyethylene vials or other special purpose containers.
  • the dantrolene compositions of the present invention can be loaded into an auto injectors/pen injector, prefilled syringes, plastic RTU bags, IV bags and the like.
  • Containers are of a size sufficient to hold one or more doses of dantrolene.
  • a stable, multidose, ready to use, non-aqueous composition comprising
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol and propylene glycol
  • non-aqueous solvent system is free from polar aprotic solvents.
  • composition comprising from about 50 mg/mL to about 150 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol from about 30% to about 90% and propylene glycol from about 10% to about 90%.
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol from about 30% to about 90% and propylene glycol from about 30% to about 90%.
  • a stable, multidose, ready to use, non-aqueous composition comprising
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol and ethanol;
  • non-aqueous solvent system is free from polar aprotic solvents; where in composition comprising from about 50 mg/mL to about 150 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol from about 30% to about 90% and propylene glycol from about 10% to about 90%.
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol from about 30% to about 90% and propylene glycol from about 5% to about 50%.
  • a stable, multidose, ready to use, non-aqueous composition comprising
  • non-aqueous solvent system suitable for injection comprises mixture of propylene glycol and ethanol
  • non-aqueous solvent system is free from polar aprotic solvents
  • composition comprising from about 50 mg/mL to about 150 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
  • non-aqueous solvent system suitable for injection comprises mixture of propylene glycol from about 10% to about 90% and ethanol from about 5% to about 50%.
  • non-aqueous solvent system suitable for injection comprises mixture of propylene glycol from about 30% to about 90% and ethanol from about 5% to about 50%.
  • a stable, multidose, ready to use, non-aqueous composition comprising
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol, propylene glycol and ethanol;
  • non-aqueous solvent system is free from polar aprotic solvents; where in composition comprising from about 50 mg/mL to about 150 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol from about 30% to about 90%, propylene glycol from about 10% to about 90% and ethanol from about 5% to about 50%.
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol from about 30% to about 90%, propylene glycol from about 30% to about 90% and ethanol from about 5% to about 50%.
  • a stable, multidose, ready to use, non-aqueous composition comprising
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol, propylene glycol and ethanol;
  • non-aqueous solvent system is free from polar aprotic solvents
  • composition comprising from about 50 mg/mL to about 150 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
  • composition is having a pH ranging from about 5.0 to about
  • a stable, multidose, ready to use, non-aqueous composition comprising
  • non-aqueous solvent system is free from polar aprotic solvents
  • composition optionally further comprising a stabilizer.
  • a stable, multidose, ready to use, non-aqueous composition comprising (i) dantrolene or pharmaceutically acceptable salts thereof
  • non-aqueous solvent system is free from polar aprotic solvents
  • composition optionally further comprising an antioxidant.
  • a stable, multidose, ready to use, non-aqueous composition comprising
  • non-aqueous solvent system is free from polar aprotic solvents
  • composition optionally further comprising an antioxidant and/or surfactant.
  • a stable, multidose, ready to use, non-aqueous composition comprising
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol, propylene glycol and ethanol;
  • non-aqueous solvent system is free from polar aprotic solvents.
  • a stable, multidose, ready to use, non-aqueous composition comprising
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol, propylene glycol and ethanol;
  • non-aqueous solvent system is free from polar aprotic solvents.
  • a stable, multidose, ready to use, non-aqueous composition comprising
  • non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol, propylene glycol and ethanol;
  • non-aqueous solvent system is free from polar aprotic solvents.
  • compositions of the invention upon reconstitution with sterile water for injection forms a uniform colloidal suspension.
  • the mean particle size of dantrolene in the colloidal suspension was less than 1 micron.
  • the mean particle size of dantrolene in the colloidal suspension was less than 0.5 micron.
  • compositions of the present invention may be prepared by measuring required quantities of propylene glycol in a container. Add suitable stabilizers to above container and stirred for 10-15 mins followed by addition of oth 1. Dispense all the required quantity of materials.
  • non-aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection used for the treatment of malignant hyperthermia and other related diseases or disorders.
  • non-aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection used for the treatment of dantrolene sensitive diseases or disorders include malignant hyperthermia, heat stroke, psychostimulant drug-induced toxicity (PDIT), pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations.
  • dantrolene sensitive diseases or disorders include malignant hyperthermia, heat stroke, psychostimulant drug-induced toxicity (PDIT), pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations.
  • PDIT psychostimulant drug-induced toxicity
  • compositions are also effective in the management of neuroleptic malignant syndrome, spasticity and Ecstasy intoxication.
  • compositions effective for the treatment or protecting from at least one cardiac arrest-related dysfunction including cardiac arrhythmia, premature ventricular contraction (PVC) induced left ventricular dysfunction, atrial fibrillation induced left ventricular
  • compositions comprising dantrolene or pharmaceutically acceptable salts alone or in combination with NMDA blocker or benzodiazepine derivatives or combinations thereof used for the treatment of neuronal reperfusion injury with ischemic neuropathy.
  • Example 1 the compositions comprising dantrolene or pharmaceutically acceptable salts alone or in combination with NMDA blocker or benzodiazepine derivatives or combinations thereof used for the treatment of neuronal reperfusion injury with ischemic neuropathy.
  • Formulations of dantrolene were prepared and evaluated chemical stability.
  • Formulation with polysorbate 80 formed smooth suspension during administration making it one of the necessary excipients. Based on the formulation trials and the data, it can be concluded that formulation with 50 mg/ mL strength containing co solvents in the said proportion along with polysorbate 80 and ethanol is necessary for formulation of non-aqueous Dantrolene compositions.
  • composition F9 upon reconstituted with sterile water for injection forms a uniform colloidal suspension and the particle size of dantrolene was measured.
  • the dantrolene particle size of test product was compared with a reference composition which is similar to RYANODEX (inhouse preparation).

Abstract

The present invention relates to a stable, multidose, ready to use, non-aqueous compositions comprising (i) dantrolene or pharmaceutically acceptable salts thereof; (ii) non-aqueous solvent system suitable for injection; wherein dantrolene was substantially dissolved in the non-aqueous solvent system; wherein non-aqueous solvent system is free of polar aprotic solvents.

Description

READY TO USE DANTROLENE COMPOSITIONS
FIELD OF THE INVENTION
The present invention relates to a stable, multidose, ready to use, non- aqueous compositions comprising (i) dantrolene or pharmaceutically acceptable salts thereof; (ii) non-aqueous solvent system suitable for injection, wherein dantrolene was substantially dissolved in the non-aqueous solvent system; wherein non-aqueous solvent system is free of polar aprotic solvents.
BACKGROUND OF THE INVENTION
Dantrolene, 1 -[(E)-[5-(4-nitrophenyl) furan-2-yl] methylideneamino] imidazolidine-2,4-dione, is a direct-acting skeletal muscle relaxant. It is the rescue agent of choice in the treatment of malignant hyperthermia, therefore widely available in most locations where anesthetics are delivered.
Dantrolene is structurally represented as
Figure imgf000002_0001
The commercial formulation Ryanodex® for injectable suspension is a sterile lyophilized powder comprising mannitol, polysorbate 80, povidone K12 and sodium hydroxide or hydrochloric acid for pH adjustment. Reconstituted RYANODEX® was administered by intravenous push at a minimum dose of 1 mg/kg for the treatment of malignant hyperthermia, whereas the
recommended prophylactic dose of RYANODEX is 2.5 mg/kg administered intravenously over a period of at least 1 minute, starting approximately 75 minutes prior to surgery.
Another commercial formulation Dantrium®is a sterile, non-pyrogenic, lyophilized formulation of dantrolene sodium for injection comprising 3000 mg mannitol, and sufficient sodium hydroxide. Dantrium® intravenous should be administered by continuous rapid intravenous push beginning at a minimum dose of 1 mg/kg, and continuing until symptoms subside or the maximum cumulative dose of 10 mg/kg has been reached.
Upon reconstitution of Dantrium®with 60 ml sterile water, a final concentration of 0.33 mg/ml of dantrolene and 50 mg/ml mannitol is achieved, i which exhibits a number of undesirable properties like cumbersome, imprecise preparation, significant time and elevated temperatures
to prepare a solution, large volume of solution to deliver an efficacious dose and large loading of mannitol can cause CNS complications.
U.S. Pat. No. 5,091 ,188 discloses, water-insoluble drugs injectable formulations as aqueous suspensions of phospholipid-coated microcrystals. Example 14 illustrates the lecithin-coated microcrystals of dantrolene.
U.S. Pat. No. 7,758,890 discloses low volume, safe for injection, colloidal dispersion of dantrolene sodium, water soluble polysorbate, dispersing agents like sorbitol and mannitol and water as a liquid carrier. Examples 1 -3 illustrates dantrolene colloidal suspension formulations and their preparation process.
U.S. Patent Application No 2003/0045587 discloses a pharmaceutical composition comprising dantrolene sodium and a solvent system comprising polar organic material comprising a sugar having at least two hydroxyl groups or an alcohol of two or three carbons having at least two hydroxyl groups or both and a second polar organic material comprising an amide group or an ammonium group or both. In a preferred embodiment polar solvent system comprising glycerol and N, N-dimethylacetamide (DMA).
The‘587 application aimed at developing formulations of dantrolene in a mixture of N, N-dimethylacetamide and glycerol (illustrated in examples 1 -5 preferably contain) are not recommended/suitable for injection because of DMA toxicity profile.
U.S. Pat. No. 9,433,608 discloses an emulsion prepared by mixing a component comprising val-dantrolene in glycerine or Vitamin E with another component comprising dantrolene in polyethylene glycol/propylene glycol/pluronic acid.
U.S. Patent Application No. 2004/0242646 discloses low volume safe for injection aqueous composition comprising dantrolene sodium and liquid carriers selected from group consisting of water, a water miscible solvent, glycerol, propylene glycol, dimethylacetamide, ethanol, polyethylene glycol, triethyl citrate, triacetin, monothioglycerol, or mixtures thereof.
In‘646 application, examples 1 -3 illustrates dantrolene colloidal suspension formulations and their preparation process. There has been no disclosure on the use of liquid carrier in preparing liquid compositions and their stability.
Although the use of non-aqueous solvents or solvent systems for the preparation of dantrolene compositions has been disclosed in the scientific and patent literatures (see for example U.S. 2003/0045587), there has been no disclosure of non-aqueous ready to use dantrolene compositions comprising high concentration of dantrolene.
Though the prior arts disclose dantrolene was dissolved in the solvents or solvent systems, they didn’t disclose the compositions comprising high concentration of dantrolene and their stability and the solvent systems disclosed in the prior arts preferably contain dimethyl acetamide which is not a preferred solvent for this type of drugs.
Surprisingly, inventors of the present application developed stable, ready-to-use, compositions comprising dantrolene and non-aqueous solvent systems. The compositions of the present invention, wherein dantrolene was substantially dissolved in the non-aqueous solvent system and the non- aqueous solvent system is free of polar aprotic solvents. The compositions of the present invention are stable for commercially significant time and also suitable for direct or instant administration.
SUMMARY OF THE INVENTION
The present invention relates to a stable, multidose, ready to use, non- aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection which is free from polar aprotic solvents.
The object of the invention is to prepare a stable, multidose, ready to use, non-aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection; wherein dantrolene was substantially dissolved in the non-aqueous solvent system.
In another aspect of the present invention provides dantrolene compositions in non-aqueous solvent systems which are free from polar aprotic solvents provides a stable, multidose, ready to use compositions. In another aspect a stable, multidose, ready to use, non-aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein
compositions comprising from about 50 mg/mL to about 150 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
The present invention relates to a stable, multidose, ready to use, non- aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system selected from the group comprising glycerol, propylene glycol, ethanol, polyethylene glycol, methanol, 1 -Butanol, 2-butanol, tertiary butanol, isopropanol, 1 -propanol and mixtures thereof.
In another aspect a stable, multidose, ready to use, non-aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system preferably comprising propylene glycol, polyethylene glycol, ethanol and combinations thereof.
In another aspect, stability of high concentrations (at least about 5%, w/v) of compound has been provided by the formulations of the present invention.
The present invention relates to a stable, multidose, ready to use, non- aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein the compositions further comprises at least one pharmaceutically acceptable excipients selected form the group of solubilizers, stabilizers, buffering agents, tonicity contributing agents, pH adjusting agents.
The present invention relates to a stable, multidose, ready to use, non- aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein the compositions is having a pH ranging from about 5.0 to about 1 1.
It is an object of this invention to provide a method for treating malignant hyperthermia and other conditions including but not limited to heat stroke, psychostimulant drug-induced toxicity (PDIT), pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations, by the use of stable, multidose, ready to use, non- aqueous compositions comprising dantrolene or its pharmaceutically acceptable salts thereof.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a stable, multidose, ready to use, non- aqueous compositions comprising (i) dantrolene or pharmaceutically acceptable salts thereof, (ii) non-aqueous solvent system suitable for injection; wherein dantrolene was substantially dissolved in the non-aqueous solvent system; wherein non-aqueous solvent system is free of polar aprotic solvents.
The present invention drawn to unexpected discovery of stable, ready to use, compositions of dantrolene in non-aqueous solvent system free from polar aprotic solvents.
The term“dantrolene” includes the compound dantrolene,
pharmaceutically acceptable salts thereof, isomers, solvates, prodrugs, complexes and hydrates, anhydrous forms thereof, and any polymorphic or amorphous forms or combinations thereof.
The term“pharmaceutically acceptable salts” includes
pharmaceutically acceptable salts, solvates, hydrates, anhydrates,
enantiomers, esters, isomers, polymorphs, tautomers, complexes and thereof.
The term“ready-to-use” refers to a liquid for parenteral administration that is not obtained by reconstituting a lyophilized product.
The terms“composition” and“formulation” refer to preparations comprising dantrolene or pharmaceutically acceptable salts thereof; in a form suitable for administration to a mammal.
The term“substantially dissolved" relates to 0.1 % to 99% of total dantrolene is dissolved in the compositions.
The term "stable" or "stability" as used herein includes both physical and chemical stability. Stability parameters include but not limited to potency, stable pH value and other physico-chemical parameters.
The term "physical stability" refers to compositions free from particles and that do not significantly change during storage.
The term "chemical stability" relates to a limited formation of impurities, limited decrease in potency and the like. The term“polar aprotic solvents” relates to a polar solvent that lack an acidic hydrogen and do not participate in hydrogen bonding (lack of O-H or N- H bonds), for example N, N-dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), dimethylformamide (DMF), hexamethyl phosphorotriamide (HMPT), dichloromethane, hydro furans (e.g. tetrahydrofuran), hydro pyrans, ethyl acetate, acetone, acetonitrile, propylene carbonate, N-methyl-2-pyrrolidone, and the like.
In one embodiment stable, multidose, ready to use, non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection.
In another embodiment stable, multidose, ready to use, non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein dantrolene was substantially dissolved in the non-aqueous solvent system.
In another embodiment stable, multidose, ready to use, non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein dantrolene was substantially dissolved in the non-aqueous solvent system; wherein non- aqueous solvent system is free of polar aprotic solvents.
In one embodiments, the stable, multidose, ready to use, non-aqueous composition comprising from about 10 mg/mL to about 200 mg/mL or from about 25 mg/ml to about 175 mg/ml or from about 50 mg/ml to about 150 mg/ml of dantrolene or pharmaceutically acceptable salts thereof.
In another embodiment, the composition comprising combination of dantrolene with other agents within the scope of the invention for example azumolene, NMDA blocker, benzodiazepine derivatives and the like, combinations thereof.
In one embodiment, the non-aqueous solvent system comprises non- aqueous solvents and their mixture thereof.
In another embodiment the non-aqueous solvent system is free from polar aprotic solvents.
In one embodiment of the invention, the composition comprising less than 5% by weight of residual water content. This residual water content may have contributed from the non-aqueous solvents used in the composition. In another embodiment of the invention, the composition comprising less than 2.5% by weight of residual water content.
In one embodiment suitable non-aqueous solvents comprise, polar protic solvents and mixtures thereof. The polar protic solvents are known in the art and include alkyl alcohols, for example ethanol, methanol, 1 -butanol, 2-butanol, 1 -propanol, isopropanol, tertiary butanol; alkyl glycols for example, ethylene glycol, propylene glycol and butylene glycol; glycerin; polyalkylene glycols, such as polyethylene glycol, polypropylene glycol, and polybutylene glycol.
In one embodiment non-aqueous solvents selected from the group comprising glycerol, propylene glycol, ethanol, polyethylene glycol, methanol, acetone, acetonitrile, 1 -Butanol, 2-butanol, tertiary butanol, isopropanol, 1 - propanol, and mixtures thereof.
In another embodiment non-aqueous solvent system preferably comprising propylene glycol, polyethylene glycol, ethanol and/or combinations thereof.
In one embodiment the stable, multidose, ready to use, non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof; non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system comprises of polyethylene glycol.
In another embodiment the stable, multidose, ready to use, non- aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof; non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system comprises the mixture of polyethylene glycol and propylene glycol.
In another embodiment the stable, multidose, ready to use, non- aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof; non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system comprises the mixture of polyethylene glycol and ethanol.
In one embodiment the stable, multidose, ready to use, non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof; non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system comprises of propylene glycol. In another embodiment the stable, multidose, ready to use, non- aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof; non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system comprises the mixture of propylene glycol and ethanol.
In one embodiment the stable, multidose, ready to use, non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof; non-aqueous solvent system suitable for injection, wherein non- aqueous solvent system comprises the mixture of polyethylene glycol, propylene glycol and ethanol.
In one embodiment, the PEG has a molecular weight ranging from about 100 g/mol to about 2,500 g/mol.
In another embodiment, the PEG has a molecular weight ranging from between about 300 g/mol to about 1000 g/mol.
In another embodiment, the PEG has an average molecular weight ranging from between about 400 g/mol to about 800 g/mol.
In one embodiment, exemplary PEG’S include PEG-300, PEG-400, PEG-600 and PEG-800.
In another embodiment, polypropylene glycol (PPG) may have a molecular weight ranging from about 200 g/mol to about 2500 g/mol.
In a preferred embodiment, exemplary poly propylene glycols include PPG-250, PPG-425, and PPG-700.
In one embodiment, the composition comprising propylene glycol in a range from about 30% to about 90% by weight of the composition;
alternatively, composition comprising propylene glycol in a range from about 10% to about 90% by weight of the composition.
In another embodiment, the composition comprising polyethylene glycol in a range from about 30% to about 90% by weight of the composition.
In another embodiment, the composition comprising ethanol in a range from about 5% to about 50% by weight of the composition.
In one embodiment, the stable, multidose, ready to use, non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection and at least one pharmaceutically acceptable excipient selected form the group of solubilizers, stabilizers, buffering agents, tonicity contributing agents, pH adjusting agents.
In one embodiment the stable, multidose, ready to use, non-aqueous composition comprising tonicity contributors including one or more of sodium chloride, potassium chloride, and alkaline substances including one or more of sodium hydroxide, potassium hydroxide, sodium carbonate and meglumine and salts.
The term“solubilizer” refers to any substance which enhances the solubility of the dantrolene in the solvents.
Suitable solubilizer comprises, but not limited to, carboxylic acid, sugar and tromethamine.
Suitable carboxylic acid comprises, but not limited to, citric acid, malic acid, tartaric acid, succinic acid, acetic acid and the like.
Suitable sugar comprises, but not limited to, monosaccharide, disaccharide and reduced sugars that are suitable for administration by subcutaneous and intravenous routes. Some examples of sugar include, but not limited to, sucrose, fructose, trehalose, xylitol, mannitol, sorbitol and the like.
In one embodiment stable, multidose, ready to use, non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein the composition is having a pH ranging from about 5.0 to about 11.
In one embodiment stable, multidose, ready to use, non-aqueous composition comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection, wherein the composition is having a pH ranging from about 7.0 to about 11.
The term“stabilizer” refers to an agent which improves the composition stability.
In one embodiment suitable stabilizers includes surfactants,
antioxidants, chelating agents, proteins, polymers and combinations thereof.
In another embodiment stabilizers include antioxidants selected from the group, but not limited to butylated hydroxyanisole (BHA), butylated hydroxyl toluene (BHT), ascorbic acid and their esters, lactic acid, benzoic acid, tocopherol (Vitamin E) and its derivatives, sodium metabisulfite, sodium bisulfite, sodium sulfite, sodium bisulfate, sodium thiosulfate, sodium acetate trihydrate, sodium formaldehyde sulfoxylate, monothioglycerol, L-cysteine, parabens, benzyl alcohol, thiourea, propyl gallate, methionine, thioglycolic acid, tartaric acid, phosphoric acid, gluconic acid, thiodipropionic acid, acetonic dicarboxylic acid, amino acids such as histidine, tryptophan, tyrosine;
Chelating agents include, but are not limited to, edetate salts, for example, edetate disodium and citric acid, ethylene glycol-bis(beta-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA) and 8-Amino-2-[(2-amino-5- methylphenoxy)methyl]-6-methoxyquinoline-N,N,N’N’-tetraacetic acid, tetrapotassium salt (QUIN-2) and the like combinations thereof.
In another embodiment proteins as stabilizers include albumin, casein, and salts of casein; Polymers include polyvinylpyrrolidone (PVP), acacia (gum arabic), carmellose sodium, dextran, collagen, gelatin, gelatin hydrosylate, sodium starch glycolate, inulin, and xanthan; suitable surfactants or block copolymer components (or mixtures thereof) include cationic surfactants, anionic surfactants, non-ionic surfactants, zwitterionic surfactants, PEGylated surfactants, block copolymer and mixtures thereof.
In another embodiment surfactants include but not limited to
polysorbates, sodium oleate, sodium dodecyl sulfate, sodium diethyl hexyl sulfosuccinate, sodium dimethyl hexyl sulfosuccinate, sodium di-2-ethyl acetate, sodium 2-ethylhexyl sulfate, sodium undecane-3-sulfate, sodium ethyl phenyl undecanoate, dimethylammonium and trimethylammonium
Surfactants, myristyl-gammapicolinium chloride, dodecyl dimethyl
ammoniopropane- 1 -sulfate, dodecyl dimethyl ammoniobutyrate,
Dodecyl trimethylene di(ammonium chloride); decyl methyl sulfonediimine; dimethyl eicosyl ammoniohexanoate, Poloxamer 188 (Pluronic
F-68), Pluronic F- 127, polyoxyl castor oil and related PEGylated
castor oil derivatives such as Cremaphore EL, Arlatone G, sorbitan
monopalmitate, Pluronic 123, and sodium 2-ethylhexanoic
acid, polyoxyethylene fatty acid esters and mixtures thereof.
In one embodiment, the dantrolene compositions of the present invention can be packaged in any suitable sterile vial or container fit for the sterile storage of a pharmaceutical such as dantrolene for extended periods of time. Suitable containers can be glass vials, i.e. treated vials, molded glass vials, and CZ resin vials, polypropylene or polyethylene vials or other special purpose containers.
In one embodiment, the dantrolene compositions of the present invention can be loaded into an auto injectors/pen injector, prefilled syringes, plastic RTU bags, IV bags and the like.
Containers are of a size sufficient to hold one or more doses of dantrolene.
In one embodiment a stable, multidose, ready to use, non-aqueous composition comprising
(i) dantrolene or pharmaceutically acceptable salts thereof
(ii) non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol and propylene glycol;
wherein dantrolene was substantially dissolved in the non-aqueous solvent system;
where in non-aqueous solvent system is free from polar aprotic solvents.
where in composition comprising from about 50 mg/mL to about 150 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
In another embodiment the non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol from about 30% to about 90% and propylene glycol from about 10% to about 90%.
In another embodiment the non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol from about 30% to about 90% and propylene glycol from about 30% to about 90%.
In one embodiment a stable, multidose, ready to use, non-aqueous composition comprising
(i) dantrolene or pharmaceutically acceptable salts thereof
(ii) non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol and ethanol;
wherein dantrolene was substantially dissolved in the non-aqueous solvent system;
where in non-aqueous solvent system is free from polar aprotic solvents; where in composition comprising from about 50 mg/mL to about 150 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
In another embodiment the non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol from about 30% to about 90% and propylene glycol from about 10% to about 90%.
In another embodiment the non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol from about 30% to about 90% and propylene glycol from about 5% to about 50%.
In one embodiment a stable, multidose, ready to use, non-aqueous composition comprising
(i) dantrolene or pharmaceutically acceptable salts thereof
(ii) non-aqueous solvent system suitable for injection comprises mixture of propylene glycol and ethanol;
wherein dantrolene was substantially dissolved in the non-aqueous solvent system;
where in non-aqueous solvent system is free from polar aprotic solvents;
where in composition comprising from about 50 mg/mL to about 150 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
In another embodiment the non-aqueous solvent system suitable for injection comprises mixture of propylene glycol from about 10% to about 90% and ethanol from about 5% to about 50%.
In another embodiment the non-aqueous solvent system suitable for injection comprises mixture of propylene glycol from about 30% to about 90% and ethanol from about 5% to about 50%.
In one embodiment a stable, multidose, ready to use, non-aqueous composition comprising
(i) dantrolene or pharmaceutically acceptable salts thereof
(ii) non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol, propylene glycol and ethanol;
wherein dantrolene was substantially dissolved in the non-aqueous solvent system;
where in non-aqueous solvent system is free from polar aprotic solvents; where in composition comprising from about 50 mg/mL to about 150 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
In another embodiment the non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol from about 30% to about 90%, propylene glycol from about 10% to about 90% and ethanol from about 5% to about 50%.
In another embodiment the non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol from about 30% to about 90%, propylene glycol from about 30% to about 90% and ethanol from about 5% to about 50%.
In one embodiment a stable, multidose, ready to use, non-aqueous composition comprising
(i) dantrolene or pharmaceutically acceptable salts thereof
(ii) non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol, propylene glycol and ethanol;
wherein dantrolene was substantially dissolved in the non-aqueous solvent system;
where in non-aqueous solvent system is free from polar aprotic solvents;
where in composition comprising from about 50 mg/mL to about 150 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
wherein the composition is having a pH ranging from about 5.0 to about
1 1 .
In one embodiment a stable, multidose, ready to use, non-aqueous composition comprising
(i) dantrolene or pharmaceutically acceptable salts thereof
(ii) non-aqueous solvent system suitable for injection;
wherein dantrolene was substantially dissolved in the non-aqueous solvent system;
where in non-aqueous solvent system is free from polar aprotic solvents;
where in composition optionally further comprising a stabilizer.
In another embodiment a stable, multidose, ready to use, non-aqueous composition comprising (i) dantrolene or pharmaceutically acceptable salts thereof
(ii) non-aqueous solvent system suitable for injection;
wherein dantrolene was substantially dissolved in the non-aqueous solvent system;
where in non-aqueous solvent system is free from polar aprotic solvents;
where in composition optionally further comprising an antioxidant.
In another embodiment a stable, multidose, ready to use, non-aqueous composition comprising
(i) dantrolene or pharmaceutically acceptable salts thereof
(ii) non-aqueous solvent system suitable for injection;
wherein dantrolene was substantially dissolved in the non-aqueous solvent system;
where in non-aqueous solvent system is free from polar aprotic solvents;
where in composition optionally further comprising an antioxidant and/or surfactant.
In one embodiment a stable, multidose, ready to use, non-aqueous composition comprising
(i) dantrolene or pharmaceutically acceptable salts thereof;
(ii) non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol, propylene glycol and ethanol;
(iii) polysorbate 80 and
(iv) monothioglycerol
wherein dantrolene was substantially dissolved in the non-aqueous solvent system;
where in non-aqueous solvent system is free from polar aprotic solvents.
In one embodiment a stable, multidose, ready to use, non-aqueous composition comprising
(i) dantrolene or pharmaceutically acceptable salts thereof;
(ii) non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol, propylene glycol and ethanol;
(iii) polysorbate 80 and (iv) alpha-tocopherol
wherein dantrolene was substantially dissolved in the non-aqueous solvent system;
where in non-aqueous solvent system is free from polar aprotic solvents.
In one embodiment a stable, multidose, ready to use, non-aqueous composition comprising
(i) dantrolene or pharmaceutically acceptable salts thereof;
(ii) non-aqueous solvent system suitable for injection comprises mixture of polyethylene glycol, propylene glycol and ethanol;
(iii) polysorbate 80 and
(iv) butylated hydroxyanisole
wherein dantrolene was substantially dissolved in the non-aqueous solvent system;
where in non-aqueous solvent system is free from polar aprotic solvents.
The compositions of the invention upon reconstitution with sterile water for injection forms a uniform colloidal suspension.
In one embodiment of the invention, the mean particle size of dantrolene in the colloidal suspension was less than 1 micron.
In another embodiment of the invention, the mean particle size of dantrolene in the colloidal suspension was less than 0.5 micron.
In another aspect, the compositions of the present invention may be prepared by measuring required quantities of propylene glycol in a container. Add suitable stabilizers to above container and stirred for 10-15 mins followed by addition of oth 1. Dispense all the required quantity of materials.
2. Required quantity of propylene glycol was weighed and to this measured quantity of antioxidant (MTG or Alpha-Tocopherol or BHA) was added and stirred for 15 mins.
3. To the above solution, PEG-300 was added and stirred to obtain a uniform solution.
4. Weighed quantity of dantrolene sodium was added to above step mixture and stirred to obtain a clear solution. 5. To the above solution, polysorbate 80 was added and stirred, further measured quantity of ethanol was added to obtain a solution.
6. The above composition was filtered through 0.22 pm filter and filled to suitable containers er solvent PEG 300 and stirred to dissolve it completely. Further, weighed quantity of dantrolene was added and stirred to dissolve it completely. Further surfactant was added to the above composition and to this ethanol was added and stirred to obtain a solution. This solution was filtered through 0.22pm filter and filled to suitable containers.
In one embodiment stable, multidose, ready to use, non-aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection used for the treatment of malignant hyperthermia and other related diseases or disorders.
In one embodiment stable, multidose, ready to use, non-aqueous compositions comprising dantrolene or pharmaceutically acceptable salts thereof, non-aqueous solvent system suitable for injection used for the treatment of dantrolene sensitive diseases or disorders include malignant hyperthermia, heat stroke, psychostimulant drug-induced toxicity (PDIT), pumphead, and other neurological, cognitive and motor dysfunction incident to iatrogenically or trauma induced situations.
In another embodiment, the compositions are also effective in the management of neuroleptic malignant syndrome, spasticity and Ecstasy intoxication.
In one embodiment of the invention, the compositions effective for the treatment or protecting from at least one cardiac arrest-related dysfunction including cardiac arrhythmia, premature ventricular contraction (PVC) induced left ventricular dysfunction, atrial fibrillation induced left ventricular
dysfunction, ventricular arrhythmia, and a combination thereof.
In one embodiment of the invention, the compositions comprising dantrolene or pharmaceutically acceptable salts alone or in combination with NMDA blocker or benzodiazepine derivatives or combinations thereof used for the treatment of neuronal reperfusion injury with ischemic neuropathy. Example 1 :
Formulations of dantrolene were prepared and evaluated chemical stability.
Table 1 : Non-aqueous compositions of Dantrolene
Figure imgf000018_0001
Manufacturing Process:
1. Dispense all the required quantity of materials.
2. Required quantity of propylene glycol was weighed and to this
measured quantity of monothioglycerol (MTG) was added and stirred for 15 mins.
3. To the above solution, PEG-300 was added and stirred to obtain a uniform solution.
4. Weighed quantity of dantrolene sodium was added to above step mixture and stirred to obtain a clear solution.
5. To the above solution, polysorbate 80 was added and stirred,
further measured quantity of ethanol was added to obtain a solution.
6. The above composition was filtered through 0.22 pm filter and filled to suitable containers.
Table 2: Stability data for the formulations of Example 1
Figure imgf000018_0002
Conclusion: Formulation trials with the higher strength of up to 100 mg/mL were carried out and it was found that formulations with strength of 70 mg/mL and above were physically unstable due to solubility as the solubility was near to saturation solubility. Though, all the formulations were chemically stable, formulations with PEG 300 or PEG 300 and Propylene Glycol were too viscous to proceed further in terms of manufacturing and administration.
Formulation with polysorbate 80 formed smooth suspension during administration making it one of the necessary excipients. Based on the formulation trials and the data, it can be concluded that formulation with 50 mg/ mL strength containing co solvents in the said proportion along with polysorbate 80 and ethanol is necessary for formulation of non-aqueous Dantrolene compositions.
Example 2:
Table 3: Non-aqueous compositions of Dantrolene
Figure imgf000019_0001
Manufacturing Process:
1. Dispense all the required quantity of materials.
2. Required quantity of propylene glycol was weighed and to this
measured quantity of antioxidant (MTG or Alpha-Tocopherol or BHA) was added and stirred for 15 mins.
3. To the above solution, PEG-300 was added and stirred to obtain a uniform solution.
4. Weighed quantity of dantrolene sodium was added to above step mixture and stirred to obtain a clear solution. 5. To the above solution, polysorbate 80 was added and stirred, further measured quantity of ethanol was added to obtain a solution.
6. The above composition was filtered through 0.22 pm filter and filled to suitable containers.
Table 4: Stability data for the formulations of Example 2
Figure imgf000020_0001
TBA: To be analysed
Conclusion: Based on the antioxidant screening trials, it can be concluded that anti-oxidant BHA is more feasible in terms of manufacturability and also provides promising stability to the multi-dose formulation.
Example 3:
The composition F9, upon reconstituted with sterile water for injection forms a uniform colloidal suspension and the particle size of dantrolene was measured. The dantrolene particle size of test product was compared with a reference composition which is similar to RYANODEX (inhouse preparation).
Figure imgf000020_0002

Claims

We Claim,
1. A stable, multidose, ready to use, non-aqueous composition comprising
(i) dantrolene or pharmaceutically acceptable salts thereof
(ii) non-aqueous solvent system suitable for injection;
wherein dantrolene was substantially dissolved in the non-aqueous solvent system;
wherein non-aqueous solvent system is free of polar aprotic solvents.
2. The composition of claim 1 , where in composition comprising from about 25 mg/mL to about 175 mg/mL of dantrolene or pharmaceutically acceptable salts thereof.
3. The composition of claim 1 wherein, composition comprising non- aqueous solvents selected from the group comprising of glycerol, propylene glycol, ethanol, polyethylene glycol, methanol, 1 -butanol, 2-butanol, tertiary butanol, isopropanol, 1 -propanol, or mixtures thereof.
4. The composition of claim 3, where in non-aqueous solvent system preferably comprising propylene glycol, polyethylene glycol, ethanol and combinations thereof.
5. The composition of claim 1 , wherein the composition further comprises at least one pharmaceutically acceptable excipients selected form the group of solubilizers, stabilizers, buffering agents, tonicity contributing agents, pH adjusting agents.
6. The composition of claim 1 , wherein the composition is having a pH ranging from about 5.0 to about 1 1.
7. The composition of claim 5, wherein the stabilizers include surfactants, antioxidants, chelating agents, proteins, polymers and
combinations thereof.
8. The composition of claim 1 , upon reconstituted with sterile water for injection forms a colloidal suspension, wherein the mean particle size of dantrolene was less than 1 micron.
9. The composition of claim 1 , used for the treatment of malignant hyperthermia, heat stroke and other related disorders.
PCT/IB2019/051986 2018-03-12 2019-03-12 Ready to use dantrolene compositions WO2019175761A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841008981 2018-03-12
IN201841008981 2018-03-12

Publications (1)

Publication Number Publication Date
WO2019175761A1 true WO2019175761A1 (en) 2019-09-19

Family

ID=67907460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/051986 WO2019175761A1 (en) 2018-03-12 2019-03-12 Ready to use dantrolene compositions

Country Status (1)

Country Link
WO (1) WO2019175761A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210236467A1 (en) * 2018-05-21 2021-08-05 Eagle Pharmaceuticals, Inc. Dantrolene formulations and methods of their use
WO2021207443A1 (en) * 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating sars-cov-2 infections
WO2021207446A1 (en) * 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating viral infections
WO2021207444A1 (en) * 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating severe acute respiratory syndrome
WO2021207445A1 (en) * 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating coronavirus infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045587A1 (en) * 2001-06-23 2003-03-06 David Anderson Solvent system
US20090093531A1 (en) * 2007-10-09 2009-04-09 Ahmad Malkawi Co-Solvent Compositions and Methods for Improved Delivery of Dantrolene Therapeutic Agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030045587A1 (en) * 2001-06-23 2003-03-06 David Anderson Solvent system
US20090093531A1 (en) * 2007-10-09 2009-04-09 Ahmad Malkawi Co-Solvent Compositions and Methods for Improved Delivery of Dantrolene Therapeutic Agents

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210236467A1 (en) * 2018-05-21 2021-08-05 Eagle Pharmaceuticals, Inc. Dantrolene formulations and methods of their use
WO2021207443A1 (en) * 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating sars-cov-2 infections
WO2021207446A1 (en) * 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating viral infections
WO2021207444A1 (en) * 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating severe acute respiratory syndrome
WO2021207445A1 (en) * 2020-04-10 2021-10-14 Eagle Pharmaceuticals, Inc. Methods of treating coronavirus infections

Similar Documents

Publication Publication Date Title
WO2019175761A1 (en) Ready to use dantrolene compositions
US9968608B2 (en) Pharmaceutical compositions comprising pemetrexed and tromethamine
US20210008035A1 (en) Liquid formulations of bendamustine
KR101053780B1 (en) Single liquid stable pharmaceutical composition containing docetaxel
EP1658848A1 (en) Formulations comprising ecteinascidin and a disaccharide
US20240091198A1 (en) Aqueous composition comprising dantrolene
JP6356064B2 (en) A new therapeutic composition comprising apomorphine as an active ingredient.
US20160296622A1 (en) Formulations of bendamustine
US5543408A (en) Crystalline anhydrous mycophenolate mofetil and intravenous formulation thereof
EP2666463A1 (en) Stabilized liquid composition comprising pemetrexed
US20090325978A1 (en) Stable lyophilized preparation
WO2017002030A1 (en) Stable liquid formulations of melphalan
WO2009051626A1 (en) Cephalosporin derivative formulation
JP4142149B2 (en) Vancomycin lyophilized formulation
WO2017175098A1 (en) Stable liquid pharmaceutical formulations of bendamustine
US20220151923A1 (en) Stable liquid compositions of pemetrexed
EP3013316B1 (en) Stable intravenous formulation
WO2016005995A2 (en) Glycol free stable liquid compositions of bendamustine
US20090062295A1 (en) Pharmaceutical Products
US11826466B2 (en) Bendamustine solution formulations
KR20190043866A (en) Stabilizing composition for aqueous suspension of entecavir fatty acid esters analogs
WO2024075135A1 (en) "stable injectable compositions of glp-2 peptide"
WO2024009319A1 (en) Liquid injectable compositions of trilaciclib
US20180028667A1 (en) Aqueous liquid agent
TW201302755A (en) Pharmaceutical composition of Temozolomide comprising amino acid stabilizer and preparation method thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19766654

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19766654

Country of ref document: EP

Kind code of ref document: A1